CLIO Cosmetics Co., Ltd. Overview
CLIO Cosmetics is a mid-sized Korean beauty brand house. It is best known for color cosmetics: base makeup (cushions), eye products (palettes, liners, mascara) and lip tints. It runs a multi-brand portfolio. The flagships are CLIO and Peripera, supported by skincare (Goodal, Dermatory), hair care (Healing Bird), body care (TYPE No.) and a health-functional-food line (TRUERX). The model is asset-light: products are co-developed with Korean OEM/ODM manufacturers and sold mainly through third-party channels. Domestically the key channel is Olive Young (H&B), which provides roughly 56–60% of domestic sales. Overseas, sales go through Amazon and offline retail in Japan, North America, Greater China, Southeast Asia and Europe/Middle East. Revenue peaked at KRW 351.4bn in FY2024 and fell 6.4% in FY2025. A channel-rationalisation program in 2025–2026 lifted operating margin to a record 13.4% in 2Q FY2026, but top-line growth remains the open question for the equity story.
What the company does
CLIO designs, brands, markets and distributes cosmetics and personal-care products. Its business-purpose statement covers import/export of cosmetics and cosmetic tools and their sale and distribution (KIND quarterly report). It does not own large-scale manufacturing. Founder Han Hyun-ok built the company in the 1990s by co-developing color cosmetics with domestic OEM/ODM manufacturers. At that time, Korean color cosmetics relied heavily on overseas production (Ajou News, 2018).
The FY2025 business report states that an internal brand organisation runs total brand management for CLIO, Peripera, Goodal, Healing Bird, Dermatory and other indie brands. This covers product planning, development, launch, branding, packaging and container design, store interior and channel-specific visual merchandising (KIND, FY2025 business report).
Company's own characterisation
In filings and IR materials, CLIO presents itself as Korea's representative color-cosmetics specialist. It traces its lineage to Clio Sangsa, which it describes as Korea's first domestic color-cosmetics brand house. Its long-running vision is "Every Pouch One CLIO": a CLIO product in every consumer's makeup pouch worldwide. Management keywords have rotated around customer experience, digital and global (2023), and customer perspective, global and digital innovation (2025) (eToday Jan 2023; TF Media May 2025; Jasoseol).
Independent characterisation
CLIO is best understood as a trend-driven brand-and-channel operator:
Value-chain position: Mid-stream. It owns the brands, concept, formulation brief, design and go-to-market. Production is outsourced to ODMs. Logistics are being upgraded through a planned new logistics centre (EB proceeds, Jan 2026).
Revenue model: Almost entirely product sales. There is no material subscription, licensing or service revenue. A small portion comes from B2B/vendor sales overseas, which declined 45% YoY in North America in 1Q FY2025 (Meritz).
Category mix: Color cosmetics dominate. In FY2023 color was about 75% of revenue and skincare about 22% (eToday, Apr 2024). In 1Q FY2024 color was 78.1% and skincare 21.9% (Meritz).
Customer types: End consumers, mainly women aged 10–30 (goinsider/DART summary). Sales go through retailers (Olive Young and other H&B stores, drugstores, variety shops, convenience stores), marketplaces (Amazon, Rakuten, Tmall, Douyin), home shopping, own e-commerce (Club Clio) and distributors.
End-markets: Korea (about 53% of 2Q FY2026 sales) and overseas (about 47%). Overseas means Japan, North America, Greater China, Southeast Asia (Vietnam is about 60% of SEA sales), and Europe/Middle East/Africa (Kiwoom Jul 2025; eToday Aug 2026).
Channel structure (Korea)
| Channel | Role / latest data point | Source |
|---|---|---|
| H&B (Olive Young-led) | Largest channel. 1Q FY2024 H&B revenue KRW 28.4bn (+15% YoY), 50.5% of domestic sales. Olive Young is about 56–60% of domestic sales in 2026. H&B grew 24% YoY in 2Q FY2026 | Meritz (May 2024); Yuanta (Jul 2026); IBK (Sep 2026); Hyundai Motor Sec (Sep 2026) |
| Online (own mall, vertical platforms, partner malls) | 1Q FY2024 KRW 20.8bn (+38%), 37.0% of domestic sales. Online +8% YoY in 2Q FY2026, led by vertical platforms | Meritz; Edaily (Sep 2026) |
| Home shopping | Peaked at KRW 8.6bn in 1Q FY2024 (+115% YoY). Down to 7% of group sales by 4Q FY2025 (11% in 1Q FY2025). Live broadcasts ended in 2026, replaced by data broadcasting | Asiae (May 2024); SmartToday (Oct 2026) |
| Duty-free | Being reduced as a high-commission channel | Meritz (Nov 2023); SmartToday (Oct 2026) |
| Offline discount / convenience (Daiso; convenience "C" chain entry in 2025) | Daiso deliberately reduced in 2026 as low-margin | Meritz (May 2025); Hyundai Motor Sec (Sep 2026) |
| Club Clio stores (own retail) | 95 stores at end-2016; cut to 77 by June 2020. Current count not publicly disclosed | Wikipedia; Dealsite (Jul 2020) |
Strategy
Stated strategy themes
Vision: "Every Pouch One CLIO", a CLIO product in every makeup pouch worldwide (company, via Jasoseol).
2023: Declared the "first year of the great global leap" (30th anniversary). Management keywords: customer experience, digital, global (eToday, Jan 2023).
2025: Keywords were customer perspective, global and digital innovation. Strategy: localise distribution and marketing by country (TF Media, May 2025). Japan, the US and Vietnam were named strategic countries. Plans also included raising the skincare share and launching skincare brands in China and Southeast Asia as a "global skincare brand-building project" (Hankyung, May 2025).
2026 (as executed): - Profit-first channel restructuring: end live home shopping in favour of data broadcasting; reduce Daiso, duty-free and large IP collaborations; use lower-fee partnerships such as the Korea Heritage Service collaboration.
-
Keep marketing focused on core brands and hero products (Korea IR Council; IBK).
-
Overseas: expand North America offline, enter Eastern Europe via Notino, build Greater China via Douyin and offline in Taiwan and Hong Kong, and reset Japan (company, Aug 2026).
Initiatives in the last 24 months
| Initiative | Date | Detail | Status | Source |
|---|---|---|---|---|
| Japan vertical integration | Apr 2024 | Bought Doowon and Kiwami; formed CLIO Japan | Integrated; restructuring in 2026 | Dealsite; Hyundai Motor Sec |
| Twinkle Pop by CLIO at 7-Eleven Japan | Jun 2024 | Convenience-store-exclusive color brand | Live | Asiae |
| North America product diversification | 2,025 | More Goodal SKUs, Costco online entry, color category expansion | Ongoing | Dailyinvest (Feb 2025); Kiwoom |
| Europe offline (Goodal) | Jun 2025 | Retail chain with about 1,400 stores; target about KRW 3bn a year | Live | Meritz |
| Channel rationalisation (Korea) | 2025–2026 | Home shopping cut from 11% to 7% of sales (1Q to 4Q FY2025); live shows ended in 2026 | Delivered; commissions −30.7% YoY in 2Q FY2026 | SmartToday; company |
| New logistics centre | Jan 2026 funding | Financed by KRW 8.42bn treasury-share EB | Under development; site and capex not disclosed | KIND |
| Ulta Beauty (Healing Bird) | Apr 2026 | Online and offline | Live | eToday |
| Olive Young US | May–Jun 2026 | Supply to US stores | Live | eToday |
| Nordstrom and Costco (US) | 2H 2026 | Planned listings | Pending | Cosinkorea |
| Notino (Europe) | 2H 2026 | Eastern European online/offline | Pending | Cosinkorea |
| Japan reset | 2,026 | Rakuten low-margin cut; SNS-viral marketing; inventory and distribution overhaul | In progress | Hyundai Motor Sec; eToday |
ESG commitments and quantified cost programs: not publicly disclosed.
Guidance and medium-term targets
| Item | Target | Outcome | Source |
|---|---|---|---|
| FY2024 revenue target | Above KRW 400bn | Missed (KRW 351.4bn) | Hana (Apr 2024) |
| FY2025 guidance: group revenue | +15% | Missed (−6.4%) | Hyundai Motor Sec via Dailyinvest (Feb 2025); Kiwoom |
| FY2025: domestic | +15% (high single digit in later decks) | Missed | Dailyinvest; Kiwoom |
| FY2025: global | +20% | Missed | Dailyinvest |
| FY2025: North America | Mid-to-high-teens growth; high-single-digit margin | Missed (US −33% in 1Q) | Kiwoom |
| FY2025: Japan | Mid-to-high-teens growth | Partial | Kiwoom |
| FY2025: Southeast Asia | Low-20s growth | Not achieved early in the year | Kiwoom |
| FY2026 formal guidance | — | — | — |
Products & Services
CLIO does not publicly disclose SKU-level revenue or pricing. The list below covers flagship lines named in filings, IR releases and press. Pricing model: retail list prices through third-party channels, with heavy promotion in H&B. Specific prices are not disclosed in filings.
CLIO (flagship color cosmetics; about 70%+ of revenue with Peripera, per Hana Oct 2024)
| Product / line | Description & positioning | Target | Latest milestone | Source |
|---|---|---|---|---|
| Kill Cover Founwear Cushion "The Original" | High-coverage cushion foundation; 20 shades in North America | Base-makeup users in Korea, NA and Asia | Growing at double digits in North America | Jasoseol (company-derived) |
| Kill Cover High Glow Cushion | Dewy-finish cushion; a high-traffic item at Olive Young | Korean H&B shoppers | Cited as a key Olive Young traffic driver (2023) | Hanwha (Dec 2023) |
| Pro Eye Palette (incl. "Air" and 2026 "Coshot Edition") | Multi-shade eyeshadow palette, a long-running hero line; IVE's Ahn Yu-jin modelled the Air version | Teens to 30s | Coshot Edition drove 2Q FY2026 H&B growth; strong in China eye category | Cosinkorea (Aug 2026); Hankyung (May 2025) |
| CLIO mascara / eye makeup on Amazon | Eye category items | US Amazon shoppers | Drove 2Q FY2026 NA sales (+33% QoQ); about KRW 5bn Amazon sales in 2Q FY2026 | eToday (Aug 2026); Hyundai Motor Sec |
| Kill Black Waterproof Pen Liner | Waterproof liquid eyeliner; historic hit known as the "Lee Hyori eyeliner" | Mass makeup users | Legacy hero product | Insight |
| Gelpresso eyeliner | Gel pencil liner marketed as smudge-proof | Mass | Legacy hero product | Insight |
| Mad Matte lip | Matte lipstick | Mass | Legacy line | Insight |
| Prism Air Shadow | Glitter/shimmer single shadow | Mass | Legacy line | Insight |
| Melacare Dual Tone-Up Sun Cream | Tone-up sunscreen sold via home shopping | Home-shopping audience | 4 consecutive sell-outs, about 45,000 units cumulative (early 2025) | Hankyung Eureka (Mar 2025) |
| Rouge Heel Jewelry Edition | Lipstick special edition | Home shopping / H&B | Launched 2024 | Asiae (May 2024) |
| Fixer Cushion (China) | Cushion launched to build the cushion category in China | Chinese consumers | 2024 China launch plan | eToday (Apr 2024) |
Peripera (color cosmetics, younger and lower price)
| Product / line | Description | Target | Latest milestone | Source |
|---|---|---|---|---|
| Ink Mood Glowy Tint / "Mood Glowy Tint" (2026 renewal) | Glossy lip tint; key Olive Young lip franchise | Teens / 20s | 2026 renewal drove 2Q FY2026 H&B growth | Cosinkorea; Hanwha (Dec 2023) |
| Essential Lip Cheek Tap (Japan) | Lip/cheek multi-use product | Japanese consumers | Performing well in Japan (1Q FY2025) | Meritz (May 2025) |
| Peripera × Care Bears (PLAZA Japan exclusive) | Character collaboration | Japan | Sold out (Mar 2024) | SmartToday (Apr 2024) |
Peripera's growing share of the mix has raised the cost-of-sales ratio in past periods because of its lower price positioning (Insight/NH research commentary).
Goodal (skincare)
| Product / line | Description | Target | Latest milestone | Source |
|---|---|---|---|---|
| Green Tangerine Vita C Dark Spot Care line (serum, etc.) | Vitamin-C brightening and dark-spot skincare | US, Japan, China | Consistently ranked high on Amazon US; main driver in Greater China via Douyin (2026) | Asiae (Jun 2024); Hankyung (May 2025); Cosinkorea (Aug 2026) |
| Houttuynia Cordata (heartleaf) sun care | Sunscreen line | Korea H&B, seasonal | Strong 2Q FY2026 seasonal sales; supported margins | Yuanta; Cosinkorea (Aug 2026) |
| Goodal at Costco online (US) | Channel listing | US club shoppers | Listing completed by mid-2025 | Kiwoom (Jul 2025) |
| Goodal Europe (retail chain of about 1,400 stores) | Offline listing | European mass retail | June 2025 entry; target about KRW 3bn a year | Meritz (May 2025) |
Dermatory (derma skincare)
| Product / line | Description | Target | Latest milestone | Source |
|---|---|---|---|---|
| Hypoallergenic derma skincare; cica pads | Sensitive-skin line that passed hypoallergenic testing | Sensitive-skin consumers | Tmall China launch (2024); North America channel expansion planned (2024) | Hankyung (May 2025); Asiae (May 2024); Hanwha (Dec 2023) |
Healing Bird (hair care)
| Product / line | Description | Target | Latest milestone | Source |
|---|---|---|---|---|
| Hair-care line (treatments, etc.) | Mass-premium hair care | Korea, US | Entered Ulta Beauty online and offline (Apr 2026); +15% YoY in 1Q FY2025 | eToday (Aug 2026); Meritz |
Other brands
| Brand | Category | Note | Source |
|---|---|---|---|
| TYPE No. | Lifestyle body care | Part of the portfolio; incubation | Hankyung Eureka (Mar 2025); Hanwha (Dec 2023) |
| TRUERX | Health functional food | Run in connection with Clio Lifecare | Hankyung Eureka (Mar 2025) |
| Twinkle Pop by CLIO | Color cosmetics made for Japan's 7-Eleven | Japan convenience channel since Jun 2024 | Asiae (Jun 2024) |
| Indie brands | Various | +28% YoY in 1Q FY2025 | Meritz |
Financial Narrative
Income statement (FY2021–FY2025)
Sources:
-
Revenue and operating profit FY2023–FY2025: CLIO IR "Market Info" (KRW m: 330,584 / 351,366 / 328,903 and 33,810 / 24,693 / 16,436).
-
FY2021–FY2022: Kiwoom (Jul 2025) and TF Media (May 2025); FY2020 revenue of KRW 218.2bn used for FY2021 growth.
-
Net income FY2025: KRW 13.22bn (Earnings Release filed 13 Feb 2026, via FinancialFilings; Valueline).
-
FY2024: about KRW 27.9bn, implied by StockAnalysis (FY2025 earnings −51.3% YoY). Kiwoom shows KRW 26.6bn and Hanwha about KRW 28bn (controlling interest). Sources differ by about KRW 1.3bn, likely a controlling vs consolidated basis difference.
-
FY2023: KRW 27.7bn (Kiwoom); Hanwha shows about KRW 28bn controlling.
-
FY2022: KRW 10.1bn (Meritz, sum of quarters).
-
FY2021: about KRW 9.2bn, derived from Meritz's +9.3% FY2022 growth figure (derived, not directly sourced).
Commentary.
FY2021–FY2023 was a strong expansion. Revenue grew 42% over two years on post-COVID demand for color cosmetics (mask-mandate removal), H&B channel dominance at Olive Young and overseas diversification into the US and Southeast Asia. Operating margin peaked at 10.2% in FY2023.
The inflection came in 2H FY2024:
-
3Q FY2024 operating profit fell 39% after heavy new-product marketing (about KRW 4bn extra YoY).
-
4Q FY2024 operating profit collapsed to KRW 0.1bn. Causes were US MoCRA shipment delays, weaker H&B reorders and cuts to home-shopping broadcasts.
FY2025 was a trough: revenue −6.4% and operating profit −33%, with an operating margin of 5.0%. 1Q FY2025 margin was only 1.3%, held down by promotional sets, giveaways and fixed-cost deleverage (Meritz).
The recovery since 4Q FY2025 comes from cost and mix, not volume:
-
4Q FY2025 operating profit KRW 7.0bn; 1Q FY2026 KRW 5.8bn; 2Q FY2026 KRW 11.6bn.
-
1H FY2026 revenue was flat (+0.4%), but operating profit rose 272.8% to KRW 17.4bn. That exceeds the whole of FY2025's KRW 16.4bn (Korea IR Council, Oct 2026).
Net income has been supported by non-operating items. 2Q FY2026 net income (KRW 13.7bn) exceeded operating profit (KRW 11.6bn). The Korea IR Council flags a one-off item of about KRW 4.5bn as a forecast variable; its nature is not detailed in the available summary.
Quarterly income statement (1Q FY2024 – 2Q FY2026)
Sources:
-
1Q24–4Q24 and 1Q25: Kiwoom, Meritz and Hanwha (company data).
-
2Q25: implied from 2Q26 growth (+5.7% revenue, +230% operating profit); eToday reports 2Q25 operating margin of 4.3%.
-
3Q25 and 4Q25: preliminary disclosures (13 Nov 2025; 13 Feb 2026) via ETFShopping.
-
1Q26: KIND/Nate (11 May 2026).
-
2Q26: company release (13 Aug 2026).
Sources: 1Q25 KRW 2.658bn and 1Q26 KRW 6.720bn (News1/Nate); 3Q25 and 4Q25 (ETFShopping); 2Q26 KRW 13.7bn (+607%); 2Q25 back-solved (derived).
2Q FY2026 cost structure (company/eToday):
-
Cost of sales: KRW 42.2bn (−4.9% YoY); COGS ratio 48.6% vs 54.0%.
-
Gross profit: KRW 44.6bn (+18.0%).
-
SG&A: KRW 33.0bn (−3.6%); SG&A ratio 38.0% vs 41.7%.
-
Sales commissions: KRW 6.4bn vs KRW 9.3bn (−30.7%).
-
Advertising and promotion: KRW 17.0bn (4Q25), KRW 13.7bn (1Q26), KRW 12.7bn (2Q26). As a share of revenue: 21.1%, 17.5%, 14.6% (IBK, Sep 2026).
Balance sheet (FY2023–FY2025)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Segment (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Domestic revenue (KRW Bn) | 103.0 | 138.1 | 184.3 | 195.5 |
Overseas revenue (KRW Bn) | 129.8 | 134.4 | 146.3 | 155.9 |
Total revenue (KRW Bn) | 232.7 | 272.5 | 330.6 | 351.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansShare of revenue (%)
| Share of revenue (%) | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Domestic share (%) | 44.3 | 50.7 | 55.7 | 55.6 |
Overseas share (%) | 55.8 | 49.3 | 44.3 | 44.4 |
YoY growth (%)
| YoY growth (%) | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Domestic growth (%) | 34.1 | 33.5 | 6.1 |
Overseas growth (%) | 3.5 | 8.9 | 6.6 |
Revenue by Segment (%)
| Category | FY2023 | 1Q FY2024 | Source |
|---|---|---|---|
Color cosmetics (% of revenue) | about 75 (71 in 3Q FY2023) | 78.1 | eToday; Meritz |
Skincare (% of revenue) | about 22 (29 in 3Q FY2023) | 21.9 | eToday; Meritz |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBrand Details
| Brand | 1Q FY2025 YoY (%) |
|---|---|
CLIO | −20 |
Peripera | −2 |
Goodal | −7 |
Healing Bird | +15 |
Dermatory | −4 |
Indie brands | +28 |
Group Entities
| Entity | Country | Function | Status / Source |
|---|---|---|---|
CLIO Cosmetics Co., Ltd. | Korea | Parent; brand owner, planning, marketing, domestic sales | KRX |
CLIO Japan (built on acquired Doowon and Kiwami) | Japan | Offline wholesale/retail distribution (Doowon); import and manufacturer-distributor licensing (Kiwami) | Acquired Apr 2024 (Dealsite; Hanwha) |
CLIO Cosmetics USA | United States | US marketing and sales presence | — |
Presence in Hong Kong, Thailand, Vietnam | Asia | Regional sales operations | — |
Clio Lifecare | Korea | Health functional foods (TRUERX) | — |
EPNS (19% stake) | Korea | Live commerce | Acquired May 2020 (Dealsite) |
Dongin Kiyeon (listed; minority shareholding) | Korea | Investee | Mentioned in Nov 2025 KIND EB rationale; stake size not disclosed |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 232.7 | 272.5 | 330.6 | 351.4 | 328.9 |
Revenue growth YoY (%) | 6.6 | 17.1 | 21.3 | 6.3 | -6.4 |
Operating profit (KRW Bn) | 13.9 | 17.9 | 33.8 | 24.7 | 16.4 |
Operating margin (%) | 6.0 | 6.6 | 10.2 | 7.0 | 5.0 |
Net income (KRW Bn) | 9.2 | 10.1 | 27.7 | 27.9 | 13.2 |
Net margin (%) | 4.0 | 3.7 | 8.4 | 7.9 | 4.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansPer-Share Data and Margin Analysis (%)
| Metric (partial disclosure) | FY2023 | FY2024 | FY2025 | Note |
|---|---|---|---|---|
EBITDA (KRW Bn) | about 36 | about 27 | — | Hanwha (May 2025) |
EBITDA margin (%) | about 10.9 | about 7.7 | — | Computed |
EPS, controlling (KRW) | 1,582 | 1,591 | about 750 (derived) | Hanwha for FY2023–24. FY2025 derived from KRW 13.2bn net income ÷ about 17.5m shares outstanding (derived) |
DPS (KRW) | — | 400 (derived) | 250 | FY2025 DPS 250, paid 23 Apr 2026. FY2024 implied from the −37.5% YoY change (ETFShopping) |
Dividend yield (%) | 1.3 | 1.4 | about 2.1 | Hanwha; StockHub |
Revenue CAGR FY2021–FY2025 (%) | — | — | 9.0 | Computed: (328.9/232.7)^(1/4) − 1 |
“—” = not publicly disclosed.
Financial Analysis
| Metric | 1Q24 | 2Q24 | 3Q24 | 4Q24 | 1Q25 | 2Q25 | 3Q25 | 4Q25 | 1Q26 | 2Q26 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 93.0 | 92.6 | 87.6 | 78.3 | 82.3 | 82.1 | 83.8 | 80.6 | 78.3 | 86.8 |
Operating profit (KRW Bn) | 8.5 | 9.6 | 6.4 | 0.1 | 1.1 | 3.5 | 4.7 | 7.0 | 5.8 | 11.6 |
Operating margin (%) | 9.1 | 10.4 | 7.3 | 0.1 | 1.3 | 4.3 | 5.6 | 8.7 | 7.4 | 13.4 |
Net income (KRW Bn)
| Net income (KRW Bn) | 1Q25 | 2Q25 | 3Q25 | 4Q25 | 1Q26 | 2Q26 |
|---|---|---|---|---|---|---|
Net income (KRW Bn) | 2.7 | 1.9 | 5.5 | 3.1 | 6.7 | 13.7 |
Balance Sheet
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total assets (KRW Bn) | 279.6 | 295.4 | 299.3 |
Current assets (KRW Bn) | 170.7 | 186.9 | 198.0 |
Non-current assets (KRW Bn) | 108.8 | 108.5 | 101.2 |
Total liabilities (KRW Bn) | 65.9 | 61.5 | 58.4 |
Current liabilities (KRW Bn) | 54.1 | 46.5 | 45.2 |
Non-current liabilities (KRW Bn) | 11.8 | 15.0 | 13.2 |
Total equity (KRW Bn) | 213.7 | 233.9 | 240.9 |
Working capital (KRW Bn) | 116.6 | 140.4 | 152.8 |
Cash and cash equivalents (KRW Bn) | 41.7 | 111.0 | 99.5 |
Net cash (KRW Bn) | 45 | 113 | — |
“—” = not publicly disclosed.
Balance Sheet (FY2022–1Q FY2026)
| Metric (partial) | FY2022 | 1Q FY2026 | Source |
|---|---|---|---|
Current assets (KRW Bn) | 129.7 | 227.1 | Valueline |
Cash and equivalents (KRW Bn) | 44.1 | 129.3 | Valueline |
Exchangeable bond liability (KRW Bn) | 0 | 7.3 | Valueline (Mar 2026) |
Cash Flow
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Operating cash flow (KRW Bn) | 35.7 | 17.3 | 13.2 |
OCF YoY change (KRW Bn) | 7.5 | -18.4 | -4.1 |
Financial Ratios (x) and Margin Analysis (%)
| Ratio | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Current ratio (x) | 3.16 | 4.02 | 4.38 |
Liabilities to equity (x) | 0.31 | 0.26 | 0.24 |
Equity ratio (%) | 76.4 | 79.2 | 80.5 |
Returns & Leverage Ratios (%)
| Ratio (partial) | FY2023 | FY2024 | FY2025 | Source |
|---|---|---|---|---|
ROE (%) | 13.7 | 12.4 | about 5.6 | Hanwha FY2023–24; FY2025 computed (13.2 ÷ average equity 237.4) |
ROA (%) | not computed | about 9.7 | about 4.4 | Computed on average total assets |
Asset turnover (x) | not computed | about 1.22 | about 1.11 | Computed |
Net debt / EBITDA | net cash | net cash | net cash | Hanwha |
Interest coverage | not meaningful (minimal debt) | not meaningful | not meaningful | — |
TTM ROE (Aug 2026) (%) | — | — | 7.15 | Valueline |
Revenue by Region
| Region | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Japan revenue (KRW Bn) | 45.7 | 38.1 | 34.9 | 40.0 |
China revenue (KRW Bn) | 36.5 | 23.5 | 18.5 | 22.5 |
Total overseas revenue (KRW Bn) | 129.8 | 134.4 | 146.3 | 155.9 |
Geographic Revenue
| Region (partial) | FY2023 | FY2024 | Source / note |
|---|---|---|---|
United States / North America (KRW Bn) | about 31 | about 30–31 | Hanwha (May 2025) shows 31 and 31. Hankyung's FY2024 mix (NA 19% of overseas) implies about 29.6 |
Southeast Asia (KRW Bn) | — | about 28 (implied) | 18% of overseas in FY2024 (Hankyung). Vietnam is about 60% of SEA |
Overseas mix: Japan / NA / SEA / China (%) | 24 / 21 / not disclosed / 13 | 26 / 19 / 18 / 14 | Hankyung (May 2025); computed for FY2023 |
“—” = not publicly disclosed.
Region Overview
| Region | 2Q FY2026 revenue (KRW Bn) | YoY (%) | Drivers |
|---|---|---|---|
Domestic | 45.7 | +10 | H&B (+24%): Pro Eye Palette Coshot Edition, Mood Glowy Tint, Goodal sun care |
Overseas total | 41.1 | +1 | 47% of group revenue |
North America | 9.1 | +58 | Amazon eye category (about KRW 5bn Amazon); Ulta (Healing Bird, Apr 2026); Olive Young US (May–Jun 2026) |
Greater China | 10.6 | +33 | Goodal Green Tangerine on Douyin; Poya (Taiwan) expansion; Don Don Donki Hong Kong |
EMEA | 3.5 | +13 | Europe/Middle East retail expansion |
Asia (Japan + SEA) | 14.9 | −19 | Japan: Rakuten low-margin channel cut, inventory and distribution reset, organisational overhaul |
Capital Markets
| Measure | Value | Source |
|---|---|---|
Price (13 Oct 2026 close) | KRW 11,210 | Korea IR Council via SmartToday |
YTD 2026 (to 12 Oct) | −9.06% | MarketScreener |
1-year return (to 4 May 2026) | −29.04% | StockAnalysis |
12-month return (to 14 May 2025) | −48.8% | Hanwha |
Peak in the cycle | KRW 45,000 (13 Jun 2024) | Hankyung |
52-week range | KRW 8,800 – 15,330 | StockHub |
Post-2Q FY2026 move | +23.7% on 14 Aug 2026 (to KRW 14,230) | Valueline; SBS Biz |
Valuation Multiples
| Multiple | CLIO | Peers | Source |
|---|---|---|---|
P/E, FY2026E | 6.4x (at KRW 11,210) | Aekyung 14.4x, Able C&C 10.1x, iFamilySC 6.7x (average 10.4x) | Korea IR Council |
P/E, TTM (1H FY2026) | 8.76x | — | Chickstock |
P/B | 0.8–0.9x (bottom of 5-year band) | — | Korea IR Council; Chickstock |
P/S, TTM | 0.66x | — | Chickstock |
TTM EPS | KRW 1,383 | — | Chickstock |
EV/EBITDA | Not publicly disclosed (FY2025 EBITDA not available) | — | — |
EV/Sales | About 0.25–0.3x (derived: market cap about 203 minus cash about 129 plus EB about 7, divided by TTM revenue about 329) | — | Computed |
Analyst Ratings & Targets
| Broker | Date | Rating | Target price (KRW) | Key estimates |
|---|---|---|---|---|
Hyundai Motor Securities | 9 Sep 2026 | Buy | 17,000 (from 14,000) | FY2026E revenue KRW 338bn, operating profit KRW 32bn; 3Q26E revenue KRW 87.7bn, operating profit KRW 7.3bn |
IBK Securities | 7 Sep 2026 | — | — | Continued 2H margin improvement |
Korea IR Council (sponsored research) | 15 Oct 2026 | No rating | — | FY2026E revenue KRW 338.6bn (+3.0%), operating profit KRW 33.3bn (+102%), operating margin 9.8% |
Investing.com consensus | Aug 2026 | — | Average 12,000 | — |
Stockopedia consensus | 2026 | — | 10,000 | Next-FY EPS KRW 1,025 |
“—” = not publicly disclosed.
Capital Markets — Dividend policy
| Item | Detail | Source |
|---|---|---|
Dividend policy | Annual cash dividend; payout about 15% (StockHub) | StockHub |
FY2025 DPS | KRW 250 (paid 23 Apr 2026) | ETFShopping |
FY2024 DPS | KRW 400 (derived from the −37.5% YoY change) | ETFShopping |
Dividend yield | About 2.0–2.1% | StockHub; Investing.com |
Buyback authorisations (2025–2026) | None identified. Treasury shares were used for the EB rather than cancelled | KIND |
Credit ratings (Moody's / S&P / Fitch) | None. The company is unrated and has no public bonds | — |
Debt maturity profile | Only the zero-coupon private EB (KRW 8.42bn, issued Jan 2026); maturity date not confirmed in accessible sources | KIND |
Analyst Conclusions
Guidance and consensus
CLIO has not published formal FY2026 guidance in accessible sources. Sell-side and sponsored-research expectations cluster around:
-
FY2026E revenue of KRW 338–339bn (+2.7% to +3.0%)
-
Operating profit of KRW 32–33bn (roughly double FY2025)
-
Operating margin of about 9.5–9.8%
The Korea IR Council models 2H FY2026 revenue of KRW 173.4bn (+5.5%) but a lower 2H margin of 9.2%. That reflects North America launch marketing and Japan restructuring costs.
Bull case
-
Margins are structurally reset. Exiting live home shopping, Daiso and large IP collaborations cut commissions by 34% in 1H FY2026 and brought the COGS ratio down to 48.6% in 2Q. If roughly 10% operating margins hold on flat sales, FY2026 operating profit doubles.
-
North America is finally omnichannel. Ulta, Olive Young US, then Nordstrom and Costco follow a +58% quarter driven by Amazon eye products, inside the largest and fastest-growing K-beauty export market (USD 2.2bn in 2025).
-
Valuation is undemanding. At 6.4x FY2026E P/E and about 0.8x P/B, with about KRW 129bn in cash, the market prices in little growth.
Bear case
-
No organic growth yet. FY2025 revenue −6.4% and 1H FY2026 +0.4%. Much of the profit recovery comes from cost cuts that cannot repeat.
-
Japan and Southeast Asia are shrinking (Asia −19% in 2Q FY2026), and the 2024 Japan acquisition has not yet delivered.
-
Brand novelty is fragile. The guidance record is poor: the FY2024 KRW 400bn target and FY2025 +15% guidance were both missed. Olive Young dependence and low-price imitation cap pricing power.
Catalysts and monitorables (next 12 months)
-
3Q FY2026 results (12–16 Nov 2026): whether operating margin holds at 8% or higher without the Amazon Prime event.
-
Nordstrom and Costco sell-through, and the North America growth rate in 4Q FY2026.
-
Japan restructuring: return to YoY growth by 1H FY2027.
-
Notino and European roll-out.
-
FY2026 dividend decision (Feb 2027) and any policy change on treasury shares under the new Korean rules.
-
Logistics-centre capex and timeline disclosure.
-
Olive Young promotion calendar and collaboration costs.
-
Any governance changes at the March 2027 AGM.
Analyst verdict
CLIO Cosmetics enters late 2026 as a company that has repaired its income statement but not yet its growth narrative. The evidence for the repair is concrete. 2Q FY2026 operating margin reached a record 13.4%. 1H operating profit exceeded all of FY2025. The drivers were deliberate decisions: exiting high-commission channels, pruning collaboration spend and lowering advertising intensity from 21% to under 15% of sales. Those decisions should largely persist. On a net-cash balance sheet with about KRW 129bn in cash, the downside appears limited, and the stock trades at the bottom of its five-year valuation band.
The harder question is whether CLIO can grow again. Revenue has fallen from KRW 351bn in FY2024 to a run-rate of about KRW 330–340bn. The brand portfolio is still about three-quarters color cosmetics in an export market increasingly led by skincare. The company's guidance record in 2024–2025 was poor. The most credible engines are North America and Greater China: the first is moving from Amazon-only to genuine omnichannel distribution, and the second is reviving through Goodal skincare on Douyin. Together they were only about KRW 20bn of quarterly revenue in 2Q FY2026, against a shrinking Japan and Southeast Asia base of about KRW 15bn.
Governance is the persistent discount factor: founder control of about 61%, a combined CEO and chair, and alumni-linked board members. Investors should not expect a governance re-rating soon.
Net assessment: CLIO is a value-with-optionality case rather than a growth story. Upside depends on proving 4–6% revenue growth while keeping operating margins near 10%. In that scenario, peer-average multiples imply meaningful upside from about KRW 11,000–12,000. Failure to grow would leave the shares range-bound but supported by cash and dividends. The 3Q and 4Q FY2026 North America results are the key evidence to watch.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Background / education | Age | Compensation (latest proxy) | Source |
|---|---|---|---|---|---|---|
Han Hyun-ok (한현옥) | Founder, CEO and Chair of the Board; largest shareholder (48.57%) | Since founding (1993) | Yonsei University, Sociology (class of 1978); earlier career in market research; Silver Tower Order of Industrial Service Merit (2018) | About 67 (founded the company at 34 in 1993; derived) | Not publicly disclosed in accessible sources | Dealsite; Ajou News; Sidae |
Yoon Sung-hoon (윤성훈) | Vice President; board member (as of 2022). Later appointed CEO of affiliate Clio Lifecare (date not confirmed) | Joined 2014 | Hyosung Group and Hansol Group (management/restructuring); CFO at Kortek and others; led the 2016 L Capital Asia investment and the 2016 IPO | — | — | Insight; Dealsite (2022); SmartToday (Apr 2024) |
Lee Sang-kyung (이상경) | Outside director | Appointed 29 Mar 2024 | Born 1955; chair of Bang Jeong-hwan Foundation; director of KB Financial Public Welfare Foundation; outside director at TBWA; Yonsei Sociology | About 71 | — | Dealsite (Apr 2024) |
Ryu Geun-hyung (류근형) | Statutory auditor | Since 2016 | Born 1958; Yonsei Sociology (same class as the CEO) | About 68 | — | Dealsite (2022, 2024) |
Kim Hyun-sook (김현숙) | Former outside director | 2018–2023 | Born 1958; about 20 years as a journalist; Yonsei English Literature; 61% board attendance in first year | — | — | Dealsite |
Outside director elected at 31 Mar 2026 AGM | Outside director | From Mar 2026 | — | — | — | goinsider (AGM result summary) |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake (%) | Date / Source |
|---|---|---|
Han Hyun-ok | 48.57 | Hankyung (May 2025) |
Han Hyun-ok and related parties (total) | 60.71 | Hankyung (May 2025); Hanwha (60.7%, "Han + 3") |
VIP Asset Management (with affiliate) | 6.7 → 4.98 | Hanwha (May 2025) → Investing.com (reported 10 Jul 2025; 872,440 shares) |
Treasury shares (pre-EB) | about 3.0 | Hanwha (May 2025). 546,730 shares (3.03%) committed to the Jan 2026 EB |
Dimensional Fund Advisors | 0.25 | Investing.com (30 Apr 2026) |
Foreign ownership | 5.3 | Hanwha (May 2025) |
Number of shareholders | 16,654 | Stockopedia |
Competitive Landscape
Key Competitors
| Competitor | Listing | Overlap with CLIO | Relative positioning | Latest scale (KRW Bn) | Source |
|---|---|---|---|---|---|
Amorepacific (Etude, Espoir, Hera, Laneige) | KOSPI | Color and skincare across Korea, Japan, US, China | Much larger, vertically integrated | 2025 domestic production by responsible seller: 3,025.6 (production value, not revenue) | MFDS via Cosmorning |
LG H&H (VDL, CNP, The Face Shop and others) | KOSPI | Color and skincare | Much larger, diversified | 2025 production: 3,918.5 (production value) | MFDS via Cosmorning |
Aekyung Industrial (LUNA, AGE20's) | KOSPI | Color (LUNA in Japan), cushion/pact (AGE20's in US/China) | Larger group; cosmetics about 37% of sales | FY2025 revenue 654.5; operating profit 21.1 | Butler |
iFamilySC (rom&nd) | KOSDAQ | Lip tints, eye products; Olive Young; Japan; Don Quijote | Most direct single-brand rival in lip/eye | FY2025 revenue 224.1; operating profit 27.1 | Butler; Kiwoom |
Able C&C (Missha, Apieu) | KOSPI | Mass color/base | Brand-store legacy, now a multi-channel turnaround | — | Hana (Oct 2026) |
APR (Medicube) | KOSPI | Skincare and devices; US Amazon | Fast-growing, much larger | — | SmartToday (context) |
d'Alba Global | KOSPI (listed 22 May 2025) | Premium skincare | Skincare-led | — | Hankyung |
Tirtir (Goodai Global) | Private | Cushions on Amazon/US | Direct cushion rival | — | — |
VT Cosmetics | KOSDAQ | Skincare (Reedle shot), Japan | Japan-focused rival | — | Hana (Oct 2026) |
Tony Moly | KOSDAQ | Mass color and skincare | Smaller | — | Hana (Oct 2026) |
Daiso private-label and low-price me-too brands | — | Low-price color | Price competition | — | Kiwoom (Jul 2025) |
Global mass players (L'Oréal/Maybelline, e.l.f., Kosé, Shiseido/Majolica) | Various | US and Japan color | Far larger scale | — | — |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | CLIO | iFamilySC | Aekyung Industrial |
|---|---|---|---|
Revenue FY2025 (KRW Bn) | 328.9 | 224.1 | 654.5 |
Revenue growth FY2025 (%) | -6.4 | 9.4 | -3.6 |
Operating profit FY2025 (KRW Bn) | 16.4 | 27.1 | 21.1 |
Operating margin FY2025 (%) | 5.0 | 12.1 | 3.2 |
Net income FY2025 (KRW Bn) | 13.2 | 21.8 | 15.1 |



